{
    "root": "889225d1-6257-4b32-b9cc-5f9c459c994a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "SIMBRINZA",
    "value": "20250311",
    "ingredients": [
        {
            "name": "Brinzolamide",
            "code": "9451Z89515"
        },
        {
            "name": "Brimonidine Tartrate",
            "code": "4S9CL2DY2H"
        },
        {
            "name": "Benzalkonium Chloride",
            "code": "F5UM2KM3W7"
        },
        {
            "name": "Boric Acid",
            "code": "R57ZHV85D4"
        },
        {
            "name": "Carbomer Homopolymer Type B (allyl Pentaerythritol Crosslinked)",
            "code": "HHT01ZNK31"
        },
        {
            "name": "Mannitol",
            "code": "3OWL53L36A"
        },
        {
            "name": "Propylene Glycol",
            "code": "6DC9Q167V3"
        },
        {
            "name": "Water",
            "code": "059QF0KO0R"
        },
        {
            "name": "Sodium Chloride",
            "code": "451W47IQ8X"
        },
        {
            "name": "Tyloxapol",
            "code": "Y27PUL9H56"
        },
        {
            "name": "Hydrochloric Acid",
            "code": "QTT17582CB"
        },
        {
            "name": "Sodium Hydroxide",
            "code": "55X04QC32I"
        }
    ],
    "indications": "simbrinza ( brinzolamide/brimonidine tartrate ophthalmic suspension ) 1 % /0.2 % fixed combination carbonic anhydrase inhibitor alpha 2 adrenergic receptor agonist indicated reduction elevated intraocular pressure ( iop ) patients open-angle glaucoma ocular hypertension .",
    "contraindications": "recommended dose one drop simbrinza affected eye ( ) three times daily . shake well . simbrinza ophthalmic suspension may used concomitantly topical ophthalmic products lower iop . one topical ophthalmic used , drugs administered least five ( 5 ) minutes apart .",
    "warningsAndPrecautions": "simbrinza ( brinzolamide/brimonidine tartrate ophthalmic suspension ) 1 % /0.2 % supplied white low density polyethylene ( ldpe ) drop-tainer® bottles natural ldpe dispensing-tip light green polypropylene cap follows : 8 ml 10 ml bottle ndc 0065-4147-27 storage handling store simbrinza 2°c 25°c ( 36°f 77°f ) . opening , simbrinza used expiration date bottle .",
    "adverseReactions": "hypersensitivity component product . ( 4.1 ) neonates infants ( age two years ) . ( 4.2 )",
    "indications_original": "SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.",
    "contraindications_original": "The recommended dose is one drop of SIMBRINZA in the affected eye(s) three times daily. Shake well before use. SIMBRINZA ophthalmic suspension may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.",
    "warningsAndPrecautions_original": "SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is supplied in white low density polyethylene (LDPE) DROP-TAINER® bottles with a natural LDPE dispensing-tip and light green polypropylene cap as follows:\n                  8 mL in a 10 mL bottle NDC 0065-4147-27  \n                  \n                     Storage and Handling\n                  \n                  Store SIMBRINZA at 2°C to 25°C (36°F to 77°F). After opening, SIMBRINZA can be used until the expiration date on the bottle.",
    "adverseReactions_original": "Hypersensitivity to any component of this product. (4.1) Neonates and infants (under the age of two years). (4.2)"
}